Gonadotropins and prostate cancer - Revisited

Urologia Internationalis

Volumn 77, Issue 4, 2006, Pages 289-296

  Thwaini, Ali ^a,b,d   Naase, Mahmoud ^b   Chinegwundoh, Frank ^a   Baithun, Suhail ^a   Ghali, Lucy ^b   Shergill, Iqbal ^c   Iles, Ray ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^c Haroldwood Hospital   (United Kingdom)

^d NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CHORIONIC GONADOTROPIN BETA SUBUNIT; DNA; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN;

CANCER CELL CULTURE; DISEASE ASSOCIATION; DNA SEQUENCE; GENE EXPRESSION; GENETIC POLYMORPHISM; HORMONE ACTION; HORMONE RELEASE; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RADIOIMMUNOASSAY; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEMEN ANALYSIS;

ANTIBODIES, NEOPLASM; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPINS; HUMANS; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33751548131     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096330     Document Type: Review

References (27)

1. Cancer Research UK - Information Resource Centre.
2. http://nobelprize.org/medicine/.
3. Mohler JL, Gaston KE, Moore DT, Schell MJ, Cohen BL, Weaver C, Petrusz P: Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol 2004;171(6 Pt 1):2277-2280.
4. Perkins GL, Slater ED, Sanders GK, Prichard JG: Serum tumor markers. Am Fam Physician 2003;68:1075-1082.
5. http://biology.clc.uc.edu/courses/bio105/sexual.htm.
6. Counis R, Laverrière JN, Garrel G, Bleux C, Cohen-Tannoudji J, Lerrant Y, Kottler ML, Magre S: Gonadotropin-releasing hormone and the control of gonadotrope function. Reprod Nutr Dev 2005;45:243-254.
7. Bevan CL: Androgen receptor in prostate cancer: cause or cure? Trends Endocrinol Metab 2005;16:395-397.
8. Douglas JA, Zuhlke KA, Beebe-Dimmer J, Levin AM, Gruber SB, Wood DP, Cooney KA: Identifying susceptibility genes for prostate cancer - a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev 2005;14:2035-2039.
9. Elkins DA, Yokomizo A, Thibodeau SN, J Schaid D, Cunningham JM, Marks A, Christensen E, McDonnell SK, Slager S, J Peterson B, J Jacobsen S, R Cerhan J, L Blute M, J Tindall D, Liu W: Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer. Prostate 2003;56:30-36.
10. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Pettersson KS, Huhtaniemi IT: Luteinizing hormone, its beta-subunit variant, and epithelial ovarian cancer: the gonadotropin hypothesis revisited. Am J Epidemiol 2001;154:43-49.
11. Hansel W, Leuschner C, Gawronska B, Enright F: Targeted destruction of prostate cancer cells and xenografts by lytic peptide-beta LH conjugates. Reprod Biol 2001;1:20-32.
12. Bodek G, Kowalczyk A, Waclawik A, Huhtaniemi I, Ziecik AJ: Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGbeta conjugate: functional characteristic and molecular mechanism of cell death pathway. Exp Biol Med (Maywood) 2005;230:421-428.
13. Fowler JE Jr, Platoff GE, Kubrock CA, Stutzman RE: Commercial radioimmunoassay for beta subunit of human chorionic gonadotropin: falsely positive determinations due to elevated serum luteinizing hormone. Cancer 1982;49:136-139.
14. Crawford RA, Iles RK, Carter PG, Caldwell CJ, Shepherd JH, Chard T: The prognostic significance of human chorionic gonadotrophin and its metabolites in women with cervical carcinoma. J Clin Pathol 1998;51:685-688.
15. Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, Berger P: Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 1998;35:212-220.
16. Sheaff MT, Martin JE, Badenoch DF, Baithun SI: Beta hCG as a prognostic marker in adenocarcinoma of the prostate. J Clin Pathol 1996;49:329-332.
17. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO: Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998;4:295-302.
18. Policastro PF, Daniels-McQueen S, Carle G, Boime I: A map of the hCG beta-LH beta gene cluster. J Biol Chem 1986;261:5907-5916.
19. Span PN, Thomas CM, Heuvel JJ, Bosch RR, Schalken JA, vd Locht L, Mensink EJ, Sweep CG: Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. J Endocrinol 2002;172:489-495.
20. Daja MM, Aghmesheh M, Ow KT, Rohde PR, Barrow KD, Russell PJ: Beta-human chorionic gonadotropin in semen: a marker for early detection of prostate cancer? Mol Urol 2000;4:421-427.
21. Wu W, Walker AM: Human chorionic gonadotropin beta (HCGbeta) down-regulates E-cadherin and promotes human prostate carcinoma cell migration and invasion. Cancer 2006;106:68-78.
22. Devi GR, Oldenkamp JR, London CA, Iversen PL: Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 2002;53:200-210.
23. Bodek G, Kowalczyk A, Waclawik A, Huhtaniemi I, Ziecik AJ: Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGbeta conjugate: functional characteristic and molecular mechanism of cell death pathway. Exp Biol Med (Maywood) 2005;230:421-428.
24. Saito S, Kumamoto Y, Ito N, Kurohata T: Human chorionic gonadotropin beta-subunit in human semen. Arch Androl 1988;20:87-99.
25. Fukutani K, Libby JM, Panko WB, Scardino PT: Human chorionic gonadotropin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter and kidney. J Urol 1983;129:74-77.
26. Broder LE, Weintraub BD, Rosen SW, Cohen MH, Tejada F: Placental proteins and their subunits as tumor markers in prostatic carcinoma. Cancer 1977;40:211-216.
27. Jacoby ES, Kicman AT, Iles RK: Identification of post-translational modifications resulting from LHbeta polymorphisms by matrix-assisted laser desorption time-of-flight mass spectrometric analysis of pituitary LHbeta core fragment. J Mol Endocrinol 2003;30:239-252.